Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Most statements about rash/skin reactions as hypersensitivity and the need for urgent care with severe allergic features are partially supported by the label’s hypersensitivity and anaphylaxis/angioedema warnings, but several claims overreach the provided labeling detail by asserting specific clinical pairings (e.g., rash with trouble breathing/swallowing or with fever/rapid worsening) and that infections occur due to immune system effects. The provided label excerpts do not explicitly support the mechanism or the exact emergency criteria phrasing.
Category Scores
Accurate Statements
Rash from Cosentyx can be part of an allergic or hypersensitivity reaction.
Supported by Section 5.2 (Serious hypersensitivity reactions including anaphylaxis, angioedema, and urticaria have been reported). Label excerpt does not explicitly mention rash, but hypersensitivity/allergic skin manifestations are within the provided hypersensitivity warning scope.
Cosentyx can cause infections as part of its safety profile.
Supported by Section 5.1 Infections and Section 6 (Infections reported in clinical trials and postmarketing experience).
Cosentyx can cause injection-site reactions.
Partially supported: the provided label excerpt includes skin/subcutaneous disorders and postmarketing immune/skin disorders, but it does not explicitly mention injection-site reactions in the pasted sections; therefore this statement is not fully supported by the supplied excerpts.
Unsupported Statements
Rash and other skin reactions may be reported as part of Cosentyx's overall safety profile.
The provided excerpts include eczematous eruptions and other skin disorders, but do not explicitly state 'rash' or 'other skin reactions' in the way claimed. Rash-specific phrasing is not explicitly supported.
Rash from Cosentyx can range from mild skin changes to more concerning reactions that require prompt medical attention.
No 'mild to concerning' rash spectrum or 'prompt medical attention' threshold is specified in the provided label excerpts.
Urgent medical care is needed if a rash is accompanied by trouble breathing or swallowing.
While the label warns of serious hypersensitivity (anaphylaxis/angioedema) and includes urticaria, the provided excerpts do not specify rash with trouble breathing/swallowing as an emergency criterion.
Urgent medical care is needed if a rash is accompanied by swelling of the face, lips, tongue, or throat.
The label states serious hypersensitivity reactions including anaphylaxis and angioedema have been reported, and anaphylactic/serious allergic reactions should be discontinued immediately; however, the provided excerpts do not explicitly define 'urgent medical care needed' language or list those exact symptoms as an emergency rule.
Urgent medical care is needed if a rash is accompanied by blistering, peeling skin, or sores in the mouth.
The provided excerpts mention eczematous eruptions and other skin disorders, but do not explicitly support blistering/peeling/sores-in-mouth with an emergency instruction or hypersensitivity framing.
Urgent medical care is needed if a rash is accompanied by fever, severe illness, or rapidly worsening rash.
No label excerpt provided specifies fever/severe illness/rapidly worsening rash as an emergency criterion.
Cosentyx side effects can include upper respiratory symptoms such as runny nose or sore throat.
The provided label excerpts do not explicitly support upper respiratory symptoms such as runny nose or sore throat as Cosentyx adverse effects.
Cosentyx can cause infections because it affects the immune system.
The label provided states COSENTYX may increase risk of infections (Section 5.1) but does not explicitly state the mechanism as 'because it affects the immune system' in the provided excerpts.
Trouble breathing or swallowing with rash may indicate a severe hypersensitivity reaction.
The label confirms severe hypersensitivity reactions (including anaphylaxis/angioedema/urticaria) but does not explicitly link trouble breathing/swallowing with rash as an indicator in the provided excerpts.
Swelling of the face, lips, tongue, or throat with rash may indicate a severe hypersensitivity reaction.
Angioedema is listed, but the label excerpts do not explicitly connect these listed sites in combination with rash as a severe hypersensitivity indicator.
Blistering, peeling skin, or sores in the mouth with rash may indicate a severe hypersensitivity reaction.
No explicit support in the provided excerpts for this rash morphologic pattern as hypersensitivity.
Fever, severe illness, or rapidly worsening rash with rash may indicate a severe hypersensitivity reaction.
No explicit support in provided excerpts for these symptom combinations indicating severe hypersensitivity.
If rash is accompanied by hives, facial swelling, or breathing difficulty, it should be treated as an emergency.
The label excerpt supports serious hypersensitivity including urticaria and angioedema and advises immediate discontinuation if anaphylactic/serious allergic reaction occurs, but does not provide the specific 'treated as an emergency' rule phrasing nor the exact combination 'rash + hives + facial swelling + breathing difficulty' in the supplied excerpts.
Contradictions
Important Omissions
Do not administer COSENTYX to patients with active TB infection; evaluate for TB and treat latent TB prior to initiation.
Importance:
Moderate
If a serious allergic reaction occurs, immediately discontinue administration (anaphylaxis/serious allergic reaction management).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several statements introduce specific emergency-trigger criteria and symptom combinations not explicitly supported by the provided label excerpts (e.g., trouble breathing/swallowing with rash; blistering/peeling/sores in mouth; fever/rapidly worsening rash). While these may align generally with serious hypersensitivity concepts, the exact criteria and urgency instructions are not fully substantiated by the pasted label text. The infection mechanism attribution is also not explicitly supported.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Emergency symptom-combination instructions and rash-specific severity spectrum are not explicitly supported by the provided label excerpts; infection mechanism language is also not directly supported.
Suggested Improvement
Rephrase to match the label excerpts more closely (e.g., cite serious hypersensitivity reactions including anaphylaxis/angioedema/urticaria and that anaphylactic/serious allergic reactions require immediate discontinuation). Avoid asserting specific emergency criteria for rash paired with particular symptoms unless explicitly stated in the supplied prescribing information.